Oxford-Harrington Rare Disease Center Introduces New Therapeutics Accelerator
Aims to advance innovative treatments for rare diseases.
The University of Oxford, in association with Harrington Discovery Institute at University Hospitals in Cleveland, announced the launch of the Oxford-Harrington Rare Disease Center Therapeutics Accelerator with an official signing event at the University of Oxford. According to a company press release, the accelerator is transatlantic initiative to identify, fund and advance breakthrough academic discoveries to deliver new treatments for the 400 million people worldwide who suffer from rare diseases.
"Harrington has been supporting the advancement of treatments for rare and other diseases for more than a decade, committing significant funds and resources to this global challenge with considerable success,” said Jonathan Stamler, MD, president, founder, Harrington Discovery Institute "Our commitment is to major unmet needs in society to better the world. This new Accelerator and extended collaboration with Oxford and Oxford Science Enterprises represents a major step forward towards finding the best medicines that improve outcomes for the millions of individuals and families affected by rare diseases."
Reference: The Oxford-Harrington Rare Disease Centre Launches Pioneering Therapeutics Accelerator to Advance Innovative Treatments for Rare Diseases. PR Newswire. October 3, 2023, Accessed October 10, 2023. https://www.prnewswire.com/news-releases/the-oxford-harrington-rare-disease-centre-launches-pioneering-therapeutics-accelerator-to-advance-innovative-treatments-for-rare-diseases-301945119.html
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
The Rise of Predictive Engagement Tools in Clinical Trials
November 22nd 2024Patient attrition can be a significant barrier to the success of a randomized controlled trial (RCT). Today, with the help of AI-powered predictive engagement tools, clinical study managers are finding ways to proactively reduce attrition rates in RCTs, and increase the effectiveness of their trial. In this guide, we look at the role AI-powered patient engagement tools play in clinical research, from the problems they’re being used to solve to the areas and indications in which they’re being deployed.
